Related Experiment Video
Updated: Nov 24, 2025

Basophil Activation Test for Allergy Diagnosis
Published on: May 31, 2021
Characteristics of Peanut Allergy Diagnosis in a US Health Care Claims Database (2011-2017)
Todd A Mahr1, Jay A Lieberman2, Tmirah Haselkorn3
1Division of Allergy, Asthma, and Immunology, Gundersen Health System, La Crosse, Wis.
Insights
Peanut allergy incidence and prevalence in US children are rising, with over a million cases by 2017. Severe reactions and healthcare use are high, indicating a significant public health burden.
Area of Science:
- Pediatric Allergy and Immunology
- Public Health Epidemiology
- Real-World Evidence Studies
Background:
- Peanut allergy is the most prevalent childhood food allergy.
- Limited real-world data exists on the burden of pediatric peanut allergy.
Purpose of the Study:
- To estimate the annual incidence and prevalence of peanut allergy in US children aged 4-17.
- To assess severe reaction rates and healthcare utilization for peanut allergy.
Main Methods:
- Utilized US healthcare claims data (2011-2017) for children aged 4-17.
- Identified peanut allergy cases via diagnostic codes and severe reaction indicators.
- Calculated incidence and prevalence, adjusting for data limitations; analyzed severe reactions and healthcare visits.
Main Results:
- Annual incidence rose from 1.7% to 5.2% (2001-2017).
- Prevalence reached 1.25 million (2.2%) in 2017 for ages 4-17.
- Over half experienced severe reactions; 37.9% from accidental exposure; 1 in 5 had emergency visits.
Conclusions:
- Peanut allergy incidence and prevalence in the US appear to be increasing.
- High rates of severe reactions and healthcare utilization underscore the considerable burden of peanut allergy.
Background:
Peanut allergy is the most common food allergy among children. Studies assessing the burden of peanut allergy in a real-world setting are limited.
Objective:
To estimate annual incidence and prevalence of peanut allergy cases among children aged 4 to 17 years and assess severe reaction and associated health care utilization rates.
Methods:
Patient longitudinal data between January 2011 and December 2017 from a geographically and payer-type representative US health care claims database were used. Peanut allergy cases were identified using diagnostic codes and/or services indicating peanut-allergy-associated severe reactions/anaphylaxis. Estimated annual incidence was defined as peanut-allergic births as a proportion of all 1-year-olds and adjusted for less than 100% data set capture, undercoding, patient underpresenting rates, and spontaneous outgrowth. Prevalence was calculated on the basis of incidence. To assess rates of severe reactions to peanut and associated health care utilization, the cohort of 720,490 peanut allergy cases identified in 2011 was evaluated over a 6-year period from 2011 to 2017.
Results:
Annual incidence increased from 1.7% to 5.2% between 2001 and 2017. Estimated prevalence in 4- to 17-year-olds was 1.25 million (2.2%) in 2017. Atopic comorbidities (asthma, 60.8%; atopic dermatitis, 61.7%) and other food allergies (35.3%) were common. Severe reactions (≥1) were observed in more than half (n = 399,806) the patients, and 37.9% were triggered by an accidental exposure. One in 5 patients (n = 144,883) visited the emergency department due to peanut exposure.
Conclusions:
Claims data suggest that the incidence and prevalence of peanut allergy in the United States may be increasing. Estimated severe reaction rates and health care utilization were high, suggesting that the burden of peanut allergy may be considerable.
Related Concept Videos
Allergic Reactions
Allergic Drug Reactions
Cross-reactivity
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

